Risk SNP-induced lncRNA-SLCC1 drives colorectal cancer through activating glycolysis signaling
Tingting Yan(Nanjing Drum Tower Hospital), Jing‐Yuan Fang(Shanghai Institute of Hematology), Penglei Jiang(Zhejiang University), Fangfang Guo(Southern Medical University), Shiyuan Lu(Second Affiliated Hospital of Zhejiang University), Jinxian Chen(Nanjing Agricultural University), Xiaoqiang Zhu(Shanghai Institute of Hematology), Chaoqin Shen(Sun Yat-sen University), Bingshe Han(Chinese Academy of Medical Sciences & Peking Union Medical College), Xianglong Tian(Shanghai Eighth People Hospital), Qiang Liu(Sun Yat-sen University), Junfang Zhang(Tongji University), Ming Zhong(Sun Yat-sen University), Yingxuan Chen(Renji Hospital), Haoyan Chen(Shanghai Jiao Tong University), Chenyang Yu(Sichuan University), Jie Hong(Shanghai Jiao Tong University)
Cited by 64
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Comprehensive review of targeted therapy for colorectal cancer
|Signal Transduction and Targeted Therapy|2020|1.7k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
m6A-dependent glycolysis enhances colorectal cancer progression
|Molecular Cancer|2020|465
LncRNA GLCC1 promotes colorectal carcinogenesis and glucose metabolism by stabilizing c-Myc
|Nature Communications|2019|434